OnSite

Typhoid IgG/IgM Combo Rapid Test

A lateral flow immunoassay for the simultaneous detection and differentiation of anti-Salmonella typhi (S. typhi) IgG and IgM in human serum, plasma and/or whole blood.

CTK Biotech, Inc.
13855 Stowe Dr,
Poway, CA 92064, USA
Tel: 858-457-8698
Fax: 858-535-1739
E-mail: info@ctkbiotech.com

EC REP
MDSS GmbH,
Schiffgraben 41.
30175 Hannover, Germany

Table of Contents

Section A) PRODUCT DESCRIPTION

1.) Product Description

The *OnSite* Typhoid IgG/IgM Combo Rapid Test is a lateral flow immunoassay for the simultaneous detection and differentiation of anti-*Salmonella typhi* (*S. typhi*) IgG and IgM in human serum, plasma and/or whole blood. It is intended to be used as a screening test and as an aid in the diagnosis of infection with *S. typhi.* Any reactive specimen with the *OnSite* Typhoid IgG/IgM Combo Rapid Test must be confirmed with alternative testing method(s).

2.) Intended Use

The *OnSite* Typhoid IgG/IgM Combo Rapid Test is intended to be used as a screening test and as an aid in the diagnosis of infection with *S. typhi*.

3.) Device Classification

- USA: Class II device
- Europe: Annex III Other
- India: Non – critical device

Section B) TECHNICAL REQUIREMENTS

1.) General Requirements Checklist

General requirements		Apply	Applied Standards	Demonstrated By:	Location:
1.	Safe use for Patient, User, Environments	Yes	EN ISO 14971 : 2012	Risk Management File	Attachment # 1
2.	Solutions To Ensure Safety, Including Elimination/ reduction of risk, Taking Appropriate Action when appropriate and informing users of residual risk	Yes	EN ISO 14971 : 2012	Risk Management File	Attachment # 1
3	They are suitable for the purposes referred to in Article 1(2)(b), & meet manufacturer stated Performance Expectations	Yes	EN 13612 : 2002	IFU & Product Performance	Attachment # 2 & Attachment # 4
4.	Product Safety and Performance must not be affected during product lifetime when exposed to normal stresses and conditions	Yes	EN ISO 23640 : 2013	Stability Study	Attachment #5
5.	Devices designed and manufactured so that performance is not adversely affected under storage and transport conditions.	Yes	EN ISO 23640 : 2013	Pouch Package Study	Attachment # 9
6.	In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use (ISO 18113-2:2009)	Yes	EN ISO 18113-2:2009	IFU	Attachment # 2
7.	In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements	Yes	EN ISO 181131:2009	IFU	Attachment # 2
8.	Sampling procedures used for acceptance testing of in vitro diagnostic medical devices - Statistical aspects	Yes	EN ISO 13975: 2003	Sampling and acceptance procedure	SOP-82-04 and WI 82-04-1

2.) Design and Manufacturing Requirements

Design and Manufacturing Requirements		Apply	Standards	Demonstrated By:	Location:
1	**CHEMICAL AND PHYSICAL PROPERTIES**				
1.1	Device characteristics and performance in relation with intended use	Yes	EN 13612 : 2002	Product Performance	Attachment #4
1.2	Risks posed by device leakage, contaminants and residues	Yes	EN ISO 14971 : 2012 EN 13641: 2002	MSDS	Attachment # 8
2	**INFECTION AND MICROBIAL CONTAMINATION**				
2.1	Reduction of the risk of infection and/or contamination	Yes	EN ISO 14971 : 2012 EN 13641:2002	Risk Management, MSDS, IFU	Attachment #1, #2 & # 8
2.2	Reduce risk of biological substances	Yes	EN ISO 14971 : 2012 EN 13641:2002	Risk Management, MSDS, IFU	Attachment #1, #2 & # 8
2.3-2.6	N/A	No	N/A	N/A	N/A
2.7	Packaging	Yes	EN ISO 14971 : 2012 EN 13640:2002	Pouch Package Study	Attachment # 9
3	**MANUFACTURING AND ENVIORNMENTAL PROPERTIES**				
3.1	Tests when connected with other devices and/or accessories	No	N/A	N/A	N/A
3.2	Contact with device materials	No	N/A	N/A	N/A
3.3	Remove risk due to outside influence. (ex. Humidity, temperature)	Yes	EN ISO 14971 : 2012 EN 13640:2002	Risk Management Stability study	Attachment # 1 & Attachment #5
3.4	Flammability	No	N/A	N/A	N/A
3.5	Safe Waste Disposal	Yes	EN ISO 14971 : 2012 EN 13640:2002	IFU, MSDS	Attachment # 2 & Attachment #8
3.6	Ergonomics	No	N/A	N/A	N/A
4-7		**No**	**N/A**	**N/A**	**N/A**
8	**MANUFACTURER INFORMATION**				
8.1	Information for use	Yes	EN1041 : 2008 EN ISO 18113 : 2011 EN ISO 15223-1:2012	Labels, IFU	Section 4.2 & Attachment #2
8.2	Standard Symbol	Yes	EN ISO 15223-1 : 2012	Labels, IFU	Section 4.2
8.3	Danger Symbol	Yes	EN ISO 15223-1 : 2012	Labels	Section 4.2
8.4	Proper Label Format	Yes	EN ISO 15223-1 : 2012	Labels	Section 4.2
8.5	Intended Purpose	Yes	EN 1041 : 2008	IFU	Attachment# 2
8.6	Device and Component Identification	Yes	EN ISO 15223-1 : 2012	Labels	Section 4.2

8.7	Instructions for use	Yes	EN 1041 : 2008 EN ISO 18113:2011	IFU	Attachment # 2

3. RISK ANALYSIS

See Attachment 1: Non-Critical Disease Combo Rapid Test Risk Management Report
The Risk of this product is negligible and no further action needs to be taken.

4. LABELS & INSTRUCTIONS FOR USE

4.1) Instructions for Use: See Attachment 2: I.F.U.

4.2) Direct Labeling of Product

See attached labeling

5.) MATERIALS SPECIFICATIONS

5.1) Material Specification

Materials		Specification
Test strip	Overall	64 ± 0.5 mm x 3.5 ± 0.3 mm with five subcomponents
	a. Sample pad	31 ± 1.5 mm x 3.5 ± 0.3 mm Absorb water within 1 second
	b. Conjugate pad	4-5 mm x 3.5 ± 0.3 mm containing recombinant S. typhii antigen and rabbit IgG conjugated with colloid gold
	c. Nitrocellulose membrane	20 ± 0.5 mm x 3.5 ± 0.3 mm, Flow rate: 4cm / 110 - 165 seconds backing spotted with monoclonal anti-human IgM (M Band), anti-*S. typhii* IgG detection reagents (G Band), and goat anti-rabbit IgG (C) lines.
	d. Absorbent pad	15 ± 0.7 mm x 3.5 ± 0.3 mm
	e. Vinyl matte adhesive	64 ± 3.3 mm x 3.5 ± 0.3 mm Pass flow rate test at 45 °C for 7 days
Recombinant *S. typhi* H antigen		Purified via affinity chromatograph ≥ 95% purity by SDS-PAGE ≥ 1 mg/mL by Bradford Protein Assay Pass Typhoid IgG/IgM Specificity and Sensitivity QC panel
S. typhi O antigen		≥ 1 mg/mL Pass Typhoid IgG/IgM Specificity and Sensitivity QC panel
Anti-human IgM		Purified via Ion Exchange chromatograph ≥ 95% purity by SDS-PAGE ≥ 2 mg/mL by OD 280nm Pass Typhoid IgG/IgM Specificity and Sensitivity QC panel
Rabbit IgG		Purified via ion-exchange chromatograph ≥ 95% purity by SDS-PAGE ≥ 5 mg/mL by OD 280nm Pass activity test (strong C band at 5 minutes)
Goat anti-rabbit IgG		Purified via ion-exchange chromatograph ≥ 95% purity by SDS-PAGE ≥ 5 mg/mL by OD280 nm Pass activity test (strong C band at 5 minutes)
Gold Chloride		Chemical formula: $HAuCl_4.3\ H_2O$
Conjugate pad fabric		Absorb water within 1 second.
Plastic Cassette		72 ± 4.1 mm x 20 ±1 mm A sample receiving well labeled S A Lysis Buffer receiving well labeled B The position of the M, G, and C lines are marked on the cassette Strip groove fits 3.5 mm x 64 mm strip Pass flow rate test with specimens

Pouch	120 ± 0.6 mm x 65 ± 3.2 mm size with 3-5 mm sealing margin. One side is printed with company information and test type. The other side is blank for labeling of production information No dirty spots Pass 3 day integrity of seal test
Plastic pipette dropper	35 ±1 µL precision, single use
Desiccant	1 ± 0.1 g
Sample Diluent Bottle	7 mL dropper bottle, 35 µL-40 µL /drop Pass vacuum leakage test
Sample Diluent Solution	10 mL ± 0.5 mL Colorless and free of particulate matter
Package Insert	Off white or white paper, 70g A 4 paper, left and right margin: 0.5 -1.0 cm; top and bottom margin: 1.0-1.5 cm. Correct art work, color printing, no dirty spots

5.2) Product Specifications

See Attachment 3: Product Specification

5.3) Component Specifications

5.3.1) Test Characteristic

Nitrocellulose based membrane pre-coated with monoclonal anti-human IgM, anti- *S. typhii* IgG detection reagents, and goat anti-rabbit IgG and a conjugate pad containing colloid gold conjugated *S. typhii* H and O antigen and Rabbit IgG-gold conjugates assembled into a strip.

5.3.2) Kit composition and specifications

Kit Box

Item	Specification
Dimension:	12.5 cm (W) x 22 cm (L) x 7.3 cm (H)
Capacity:	30 cassette test devices

Kit Composition

Composition	Specification
1. Device	30 single use devices in each kit. Each is individually sealed, and contains two items inside 1. One cassette device composed of a test strip and a plastic housing cassette. 2. One desiccant: 1 g 3. One Plastic Dropper
2. Sample Diluent	5 mL Sample diluent in a dropper bottle 1 bottle in each kit
3. Package insert	One insert each kit

Shipping Carton Box

Item	Specification
Dimension:	54 cm (w) x 46 cm (L) x 41cm (H)
Materials:	Double side, colligated materials. Standard with 80 Kg
Capacity	40 kits of 30 tests

5.3.3) Test Appearance

The *Onsite* Typhoid IgG/IgM Combo Rapid Test device is a cassette device. The device has following letters on the surface of the cassette:

M: Location of the IgM test band
G: Location of the IgG test band
C: Location of the Control band
S: Sample receiving well



Both Test bands and the Control band in the result window are not visible before applying any samples.



If a specimen is applied and both the M and C bands appear, the test indicates the presence of anti-S. typhii IgM in the specimen. The result is IgM positive or reactive.

If a specimen is applied and both the G and C bands appear, the test indicates the presence of anti- S. typhii IgG in the specimen. The result is IgG positive or reactive

If a specimen is applied and both the M and G bands in addition to the C band develops, the test indicates the presence of anti-S. thyphii IgG and IgM in the specimen. The result is both IgG and IgM positive or reactive.

If a specimen is applied only the C band appears, the result is negative or non reactive. The Control band is used for procedural control. The Control line should always appear if the procedure is performed properly and the test reagents are working.



6.) CLINICAL STUDIES & PERFORMANCE EVALUATIONS

See Attachment 4: Product Performance

7.) STABILITY STUDIES

See Attachment 5: Stability Study

8.) MANUFACTURING

8.1) Manufacturing Process

The entire manufacturing process has seven sequential process steps and is jointly accomplished by seven production groups

Step #1 **Conjugate recombinant *S. Typhii* H and O antigen and Rabbit IgG with colloid gold and preparation of conjugation pad**

- Preparation of gold chloride solution. This solution is made by mixing 0.04% gold chloride and 0.068% sodium citrate
- Add *S. typhii* H and O antigen and Rabbit IgG to the above solution, mix well, incubate for 20 minutes at room temperature
- Add conjugation buffer, incubate for 15 minutes at room temperature
- Centrifuge
- Collect precipitants and wash with PB wash buffer
- Dissolve the conjugates with conjugate suspension buffer
- Use the QC specificity and sensitivity panel and reference reagents if necessary to determine the working concentration of the conjugate.
- Dilute the gold conjugates with the conjugate diluent
- Dispense the diluted conjugates to the conjugate pad material
- Dry the conjugate pad
- Cut the dried conjugate pads into strips at the size of 4 -5 mm x 30 cm.
- Seal the strips until use
- Inspect the conjugate pad with the QC sensitivity and specificity panels and reference reagents if necessary

Step #2 **Coat M, G, and C band on the NC membrane**

- Preparation of membrane lamination: Fix a 20 mm x 300 mm of nitrocellulose membrane onto the 300 mm x 66 mm of vinyl matte adhesive.
- According to the incoming material QC inspection result, prepare the M band (anti-human IgM), G band(S. typhii IgG detection reagents), and C band (goat anti-rabbit IgG) coating solutions.
- Dispense the reagents to the M, G, and C positions on the membrane with the coating machine.
- The coated membrane is then dried

Step #3 **Lamination**

- Use the QC control panel to inspect the conjugate pad strips and coated membrane prepared in Step 1 and 2 above.
- Prepare sample pad material at the size of 3.1 cm x 30 cm.
- Prepare absorbent pad material at the size of 1.5 cm x 30 cm.
- Assemble all the components to sheet according to scheme illustrated below
- Laminate the components according to scheme illustrated below
- Inspect each laminated sheet to make sure it is correctly assembled
- QC samples the uncut sheet with the QC sensitivity, specificity, reproducibility, interference and stability panels.

[Cross Section Scheme of Lamination]



1. Vinyl matte adhesive
2. NC membrane coated with M, G, and C band.
3. Gold conjugate pad
4. Sample pad
5. Absorbent pad

Step #4 **Cutting**

- Laminated sheets are cut into the size of 3.5 mm x 68 mm.
- The size of the strip is inspected at the beginning, middle and end of the run.

Step #5 **Cassette Assembling and Sealing**

- Pouch is labeled with name, mfg date, exp. date, and catalog, according to the documentation
- Assemble the cut strip into the plastic housing cassette and press to close the cassette
- Pack one cassette and one desiccant to each pouch
- Seal the pouch with the heat sealing machine
- Inspect packing process by reconciliation of the quantity of components picked, the quantity of pouch assembled, and the quantity of unused components.

Step #6 **Preparation of Sample Diluent**

- Prepare Sample Diluent Buffer according to formulation
- Aliquot 5 mL into each dropper bottle
- Ensure all bottles are properly labeled
- Inspect all the bottles for leakage at 2 Psi for 2 minutes.

Step #7 **Unit and Carton Packing**

- Pick up all required components (Sample Diluent, Droppers, Devices) and labels including package inserts, zip lock bag (bulk package) and kit box
- Pack to unit
- Pack to carton
- Inspect packing process by reconciliation of the quantity of components picked, the quantity of units packed, and the quantity of unpacked components
- Packed product is moved to the quarantine area awaiting Final Acceptance Inspection

8.2) Manufacturing Flow Chart



8.3) Production Specifications

Production Process	Specification
Pre-run Inspection	Antigen or Antibody has less than 10% degradation by SDS-PAGE
Colloid Gold Solution	Validated process
Conjugation	First run inspection passes QC panel Conjugate pad is uniformly soaked with conjugates by 100% visual inspection Dryness of the conjugate pad Conjugate pad passes test with QC panel
Coating	The dispensing volume is calibrated at the start of the process by checking the accuracy of the volumes dispensed. M, G, and C bands are coated at designated area and inspected at the start run, middle run, and final run 1.0 mm coating line by 100% visual inspection. Dryness of the membrane Coated membrane passes test with QC panel
Lamination	First run inspection passes test with QC panel All the components are laminated correctly by visual inspection according to Inspection Sample Plan.
Cutting	3.5 $\pm$ 0.1 mm wide each strip verified by inspection at start of run, middle-run, and final run.
Cassette assembling and pouching	All the strips are properly assembled into the cassettes by visual inspection during processing. All the pouches are labeled correctly by visual inspection. All the components are packed correctly by reconciliation of the quantity of the components picked and used.
Preparation of Sample Diluent	Solution is made with the correct formulation. Fill in volume 5 mL $\pm$ 0.5 mL based on the sampling plan No leaking on 100% test inspection
Unit Packing	All the components are packed correctly by reconciliation of the quantity of the components picked and packed.
Carton packing	Correct quantity of the units is packed by reconciliation of the quantity of the units picked and packed.

8.4) Documentation of Quality System

This product is manufactured in a facility certified to be in accordance with the ISO 13485 Quality System

See Attachment 6: ISO Certification

9.) BATCH RELEASE CRITERIA

Quality Control Inspection and Specifications:
Quality control inspection is performed on all raw materials and intermediate components produced, as well as the assembled kits. The inspection of the product is based on the following protocols:

9.1) Incoming Material Inspection

Incoming Material Inspections are performed on all in-coming raw materials. The quarantined raw materials are sampled per Inspection Sample Plan by QC department for inspection per specification described at section 5.1
Upon inspection, the QC supervisor will endorse the inspection data and assign quality status to the raw materials accordingly.
Only approved raw materials are used for production of product.

9.2) In-Process Inspection

All lots of individual intermediate components produced are inspected and tested during the process. A systematic sampling of each individual lot of intermediate components is taken for In-Process Inspection per specification described at section 5.1
Function tests are performed by assaying the intermediate components with the QC control panel, and with a reference intermediate component on the *OnSite* Typhoid IgG/IgM Combo Rapid Test if necessary. Physical inspections of the test components, such as the fill volume, appearance, and physical status are also carried out.
Upon analyzing the inspection results, the QC supervisor will assign the quality status of the intermediate components. The approved intermediate components are moved from the quarantined storage area to the approved storage area.
Components that do not pass inspection will be rejected and not used in production.

9.3) Final Acceptance Inspection

Final acceptance inspection is carried out once all the components are assembled into the final packing unit. The inspection is to ensure only the product that meets the specification is released for distribution. The inspection includes:

- Document Inspection: Inspection of all production work records
- Physical Inspection: Inspect based on the Sampling Plan. The inspection includes checking the labels, lot number and expiration date of the individual components as well as the assembled kit. Inspection is also performed to ensure that all the components are packed.
- Performance Inspection: Around 250 tests submitted by the Production group are inspected with four *Onsite* Typhoid IgG/IgM QC control panels. The

panels consist of 50 members of a specificity panel, 7 members of a sensitivity panel, 3 members of a precision panel, and 3 members of an interference panel for testing product specificity, sensitivity, precision, stability and interference

- Kits are ready for shipment once they have passed this final stage of QC inspection.
- QA will endorse the release of the product and retain at least 250 tests for future analysis.

9.4) Procedure of the Final Acceptance Inspection

Introduction:
Each kit of *Onsite* Typhoid IgG/IgM Combo Rapid Test (R0161C) contains following components:

a. 30 test devices, each sealed in a foil pouch with three items inside:
   - One cassette device
   - One desiccant
   - Plastic Dropper
b. Sample Diluent (1 bottle, 5 mL)
c. One package insert (instruction for use

Quality control evaluation is performed on every lot of these components.

Inspection Procedures:

The quality control procedures used for evaluation of the finished products are:

a. Physical Inspection
   According to the Inspection Sample Plan, obtain the required quantity of tests, inspect following parameters:
   - Content in each package: Make sure each pack contains the correct quantity of components
   - Labels: Make sure all labels correspond to documentation
   - Pouch Integrity: Make sure the pouch is sealed properly
   - Pouch content: Open pouch to check contents. Make sure all the contents are included.
   - Sample Diluent Buffer Integrity: Make sure no leakage is visible

   Record the number of the defects observed. Refer to the Acceptance Number (Ac). Pass inspection if the number (Ac) is less than the maximum allowable defects or defectives in a sample for the lot to be accepted based on the sampling plan.

b. Performance Inspection
   Each lot of the *Onsite* Typhoid IgG/IgM Combo Rapid Test is inspected for its sensitivity, specificity, precision, stability, and interference.
   - Sensitivity Inspection
     - Inspection is carried with the *Onsite* Typhoid IgG/IgM Sensitivity QC

panel. The panel consists of 7 members, numbered SM-R0161-1 to 7.
- The assay is performed and interpreted using the procedure described in the Product Insert.
- Each member specimen is assayed in duplicate.

- Specificity Inspection
  - Inspection is carried with the *Onsite* Typhoid IgG/IgM Specificity QC panel. The panel consists of 50 members, numbered SM-R0161-11 to 60.
  - The assay is performed and interpreted using the procedure described in the Product Insert

- Precision Inspection
  - Inspection is carried out with a precision panel consisting of a weak positive, Typhoid IgG and IgM sample and a negative sample.
  - The assay is performed and interpreted using the procedure described in the Product Insert.
  - Each sample is assayed in 10 replicates. 30 Devices are used for the inspection.
  - The flow rate of each device is recorded during the inspection.

- Stability Inspection
  - The stability Inspection is carried out with a 45°C 3 day accelerated stability protocol. 14 devices are incubated at the 45°C accelerated stability chamber for 3 days. Inspection is carried with the 7 members of the Sensitivity Panel.

- Interference Inspection
  - Inspection is carried out with the Combo Rapid Test Interference Panel. The panel consists of 3 members of the specimens obtained from pregnant women, autoimmune patients. Each specimen is tested in duplicate.
  - The assay is performed and interpreted using the procedure described in the Product Insert.

c. Acceptance Criteria

- The Sensitivity Inspection result must meet the specification indicated in the following table.

Typhoid IgG/IgM Combo Rapid Test Precision Panel (WI-SM-R0161)	Runs	M line IgM	G line IgG	C line	Flow Rate
SM-R0161-1 (Typhoid IgM level 1)	2	Strong	Negative	Strong	5 minutes
SM-R0161-2 (Typhoid IgM level 2)	2	Medium	Negative	Strong	5 minutes
SM-R0161-3 (Typhoid IgM level 3)	2	Weak	Negative	Strong	5 minutes
SM-R0161-4 (Typhoid IgG level 1)	2	Negative	Strong	Strong	5 minutes
SM-R0161-5 (Typhoid IgG level 2)	2	Negative	Medium	Strong	5 minutes
SM-R0161-6 (Typhoid IgG level 3)	2	Negative	Weak	Strong	5 minutes
SM-R0161-7 (Negative)	2	Negative	Negative	Strong	5 minutes

- The Precision Inspection result must meet the specification indicated in the following table.

Typhoid IgG/IgM Combo Rapid Test Precision Panel (WI-SM-R0161)	Runs	M Line IgM	G Line IgG	C Line	Flow Rate
SM-R0161-3 (Typhoid IgM level 3)	10	Weak Positive	Negative	Strong	5 mins
SM-R0161-6 (Typhoid IgG level 3)	10	Negative	Weak Positive	Strong	5 mins
SM-R0161-7 (Negative)	10	Negative	Negative	Strong	5 mins

- The Specificity Inspection result must meet the specification indicated in the following table.

Typhoid IgG/IgM Combo Rapid Test Specificity Panel (WI-SM-R0161)	Sample (N)	Negativity (%)
SM-R0161-11 to 60	50	95% Negative

- The Stability Inspection result must meet the specification indicated in the following table.

Typhoid IgG/IgM Rapid Test Stability Panel (WI-SM-R0161)	Number	M line	G line	C line	Flow Rate
SM-R0161-P1 to P3	3	Strong	Negative	Strong	5 minutes
SM-R0161-P4 to P6	3	Weak	Negative	Strong	5 minutes
SM-R0161-P7 to P9	3	Negative	Medium	Strong	5 minutes
SM-R0161-P10 to P12	3	Negative	Weak	Strong	5 minutes
SM-R0161-N1 to N3	3	Negative	Negative	Strong	5 minutes

- The Interference Inspection result must meet the specification indicated in the following table.

Rapid Test Interference Panel	Runs	Result
SM-R0000-RF1	2	Negative
SM-R0000-RF2	2	Negative
SM-R0000-PW	2	Negative

d. Reference Components Used in QC
The reference components used for inspection of individual intermediate components are approved components from previous production lots. These reference components are tested to ensure that results obtained are within the QC specification for the product.

e. See Attachment 7: Certificate of Analysis.

10.) CONCLUSION

The *Onsite* Typhoid IgG/IgM Combo Rapid Test is developed, manufactured, and marketed according to the ISO13485 quality standard. In comparison with a commercial IgM EIA kit, the test has a 91.2% Relative Sensitivity, 99% Relative Specificity and a 97.9% Overall Agreement for the detection of IgM and a 92.9% Relative Sensitivity, 99% Relative Specificity and 98.5 % Overall Agreement for the detection of IgG. The test does not require equipment and can be performed by technicians with minimal training. It can be stored for 24 months at room temperature. Thus, the test is deemed acceptable for marketing and sale wherever the regulatory requirement is completed.